Clinical trials: Non Proliferative Diabetic Retinopathy
Non Proliferative Diabetic Retinopathy(NPDR)
Clinical Study on Prognosis of Patients With Severe NPDR Undergoing Vitrectomy
To investigate the prognosis of retinal structure and function after vitrectomy in patients with severe non-proliferative diabetic retinopathy, to explore the feasibility of vitrectomy in patients with severe non-proliferative…
- Trial name
- NCT05852132
- Testing
- pars plana vitrectomy(PPV), Pars plana vitrectomy(PPV) +Panretinal photocoagulation(PRP), Panretinal photocoagulation(PRP)
- Where
- China
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Fei Gao
Non-proliferative Diabetic Retinopathy
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05695417
- Testing
- OTX-TKI
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- Ocular Therapeutix, Inc.
Non Proliferative Diabetic Retinopathy
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR
It is estimated that there are about 600 million diabetes mellitus (DM) patients all over the world until 2040，and almost 50% of whom have some degree of diabetic retinopathy (DR) at any given time.
- Trial name
- NCT04103671
- Testing
- Prompt panretinal photocoagulation, 25G Pars-plana vitrectomy
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
NPDR - Non Proliferative Diabetic Retinopathy
Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2
Characterization of Retinal vascular disease in eyes with mild to moderate NPDR in Diabetes type 2, using novel non-invasive Imaging methods, in a longitudinal, prospective and interventional clinical Study with 2 years of…
- Trial name
- CORDIS (NCT03696810)
- Testing
- Laboratory tests
- Where
- Portugal
- Volunteers
- 141 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Non Proliferative Diabetic Retinopathy
Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy
This clinical trial is a multi-center, double-blind, randomized, placebo controlled , parallel design, superiority, phase 4 study to evaluate the efficacy and safety of Entelon 50mg in 396 patients with non-proliferative diabetic…
- Trial name
- NCT05358080
- Testing
- Entelon Tab. 50mg
- Where
- South Korea
- Volunteers
- 396 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic
Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy
Diabetic retinopathy has been found progress in 20-70% diabetic patient after cataract phacoemulsification surgery. Intravitreal injection of anti-VEGF Ranibizumab is an important treatment for diabetic retinopathy including…
- Conditions
- Mild Non-proliferative Diabetic Retinopathy, Cataract Diabetic, Diabetic Retinopathy
- Trial name
- NCT05386160
- Testing
- Ranibizumab Injection [Lucentis], Phacoemulsification
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Ruijin Hospital
Neovascular Age-related Macular Edema, Diabetic Macular Edema
Anti-VEGF in Real-world
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of…
- Conditions
- Neovascular Age-related Macular Edema, Diabetic Macular Edema, Choroidal Neovascular Membrane, Non-proliferative Diabetic Retinopathy
- Trial name
- NCT05222633
- Testing
- Ranibizumab, Aflibercept, Conbercept
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wenbin Wei
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema
Ultra-wide field fluorescein angiography can detect the response of anti VGEF therapy such as Avastin on retinal ischemia in the setting of diabetic macular edema.
- Conditions
- Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT02096874
- Testing
- Bevacizumab
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- King Khaled Eye Specialist Hospital
Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.
- Conditions
- Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Trial name
- NCT01571232
- Testing
- dexamethasone intravitreal implant, intravitreal bevacizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Retina Macula Institute
Diabetic Macular Edema, Sleep Apnea
Diabetic Macular Edema - Obstructive Sleep Apnea Relationship Study
The purpose of this study is to evaluate the relationship between DME and obstructive sleep apnea (OSA). OSA impacts millions of North Americans, many of whom are undiagnosed.
- Conditions
- Diabetic Macular Edema, Sleep Apnea, Non Proliferative Diabetic Retinopathy
- Trial name
- DME-OSA (NCT03597815)
- Testing
- Aflibercept 40 MG/ML [Eylea], OSA diagnostic test - overnight sleep study, CPAP therapy for OSA positive patients
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Uptown Eye Specialists
Non-proliferative Diabetic Retinopathy
Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy
In this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will be included and divided randomly into 2 groups: Intravitreal Bevacizumab group (50 eyes) that receive 6 bimonthly intravitreal…
- Trial name
- NCT04511715
- Testing
- Intravitreal Bevacizumab IVB, Follow-up with regular examination for determination of DR progression
- Volunteers
- 100 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Severe Non-proliferative Diabetic Retinopathy
Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy
Diabetic retinopathy (DR) is a leading cause of new cases of blindness in people aged 20 to 65 years worldwide. Patients with DR may go on to develop a more severe form of the disease called Proliferative Diabetic Retinopathy…
- Trial name
- PRPhS (NCT02309502)
- Testing
- Green Pascal, Yellow Pascal
- Where
- United Kingdom
- Sponsor
- Manchester University NHS Foundation Trust
Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy New Vessels on Disc
The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR)
Commonly know that one of the complications caused by Diabetes Mellitus (DM) is microangiopathy. Microangiopathy in the long term may lead to neuropathy of the corneal nerves.
- Conditions
- Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy New Vessels on Disc, Dry Eye Syndromes
- Trial name
- NCT04000789
- Testing
- Sodium Hyaluronate, Vitamin A, Vitamin E
- Volunteers
- 96 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Moderate Non-proliferative Diabetic Retinopathy
The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy
The purpose of this study is to evaluate the role of alpha lipoic acid in patients who have moderate non-proliferative diabetic retinopathy.
- Trial name
- ALA-TPD (NCT01880372)
- Testing
- Alpha Lipoic Acid
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Ferris State University
Non-Proliferative Diabetic Retinopathy
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
A Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.
- Trial name
- NCT02435862
- Testing
- 1.0mg Luminate®, 2.0mg Luminate®, 3.0mg Luminate®
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Allegro Ophthalmics, LLC
Severe Non-proliferative Diabetic Retinopathy
Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR
This randomized, parallel controlled, clinical-trial aims to evaluate the therapeutic efficacy of 532nm laser partially subthreshold panretinal photocoagulation with PASCAL endpoint management function for severe…
- Trial name
- S-PRP (NCT01759121)
- Testing
- T-PRP, S-PRP
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Non-proliferative Diabetic Retinopathy
Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy
The purpose of this study is to evaluate the efficacy and safety of Compound Danshen Dripping Pills in patients with diabetic retinopathy(Syndrome Of Qi-Stagnation and Blood Stasis).
- Trial name
- NCT02388984
- Testing
- Compound danshen dripping pills
- Where
- 16 sites in China
- Volunteers
- 480 people
- Sponsor
- Tasly Pharmaceuticals, Inc.
Diabetic Non-proliferative Retinopathy, Type2 Diabetes
Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy
This study include 384 Participants with diabetic non-proliferative retinopathy Design Method: Randomized, double blind, placebo controlled and multicenter clinical study.
- Trial name
- NCT03025399
- Testing
- Tangwang prescription
- Volunteers
- 384 people
- Sponsor
- Fengmei Lian
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research